NDA 019194 · Bausch
Syprine
Trientine Hydrochloride · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 3, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Nov 8, 1985
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
5 Phase 3, 1 recruiting
FAERS reports
184
106 serious, 18 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2020.
INDICATIONS AND USAGE Syprine is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with Syprine is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. Syprine and penicillamine cannot be considered interchangeable. Syprine should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, Syprine is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, Syprine was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Syprine is not indicated for treatment of biliary cirrhosis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 8, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- SYPRINE · TRIENTINE HYDROCHLORIDE 250MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Trientine" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson DiseasePivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT03403205 · 214 participants · Start Feb 22, 2018 · Primary completion Jun 30, 2023
Drug: ALXN1840; SoC Therapy · For: Wilson Disease
Sites: Los Angeles, California; New Haven, Connecticut; Chicago, Illinois · 56 sites in all
- The Efficacy and Mechanism of Trientine in Patients With Hypertrophic CardiomyopathyPivotal-lookingCompleted
Manchester University NHS Foundation TrustGovernment (non-federal)
NCT04706429 · 154 participants · Start Dec 1, 2020 · Primary completion Apr 30, 2024
Drug: Trientine; Placebo · For: Hypertrophic Cardiomyopathy
Sites: Aberdeen, United Kingdom; Leicester, United Kingdom; Liverpool, United Kingdom · 7 sites in all
- Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-PenicillamineStatus unknown
Univar BVIndustry
NCT02426905 · 90 participants (planned) · Start Jan 2016 · Primary completion May 2018
Drug: trientine dihydrochloride · For: Wilson Disease
Sites: Heidelberg, Germany; Goudi, Greece; Milan, Italy · 4 sites in all
- Study of Tetrathiomolybdate in Patients With Wilson DiseasePivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00004339 · 90 participants · Start Jan 1994
Drug: tetrathiomolybdate; trientine · For: Wilson Disease
Sites: Ann Arbor, Michigan
- Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's DiseasePivotal-lookingCompleted
OrphalanIndustry
NCT03539952 · 77 participants · Start Sep 3, 2018 · Primary completion Aug 19, 2020
Drug: Penicillamine (D1-W12); TETA 4HCL (W12-60) and 2 more · For: Wilson Disease
Sites: New Haven, Connecticut; Leuven, Belgium; Curitiba, Brazil · 15 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT01178112 · 56 participants · Start Jul 2010 · Primary completion Aug 2014
Drug: Trientine; Carboplatin and 2 more · For: Advanced Cancers
Sites: Houston, Texas
- Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseasePivotal-lookingTerminated
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT05047523 · 40 participants · Start Sep 13, 2021 · Primary completion Jun 26, 2023
Drug: ALXN1840; Standard of Care · For: Wilson Disease
Sites: Parkville, Australia; South Brisbane, Australia; Lille, France · 20 sites in all
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.Pivotal-lookingRecruiting
OrphalanIndustry
NCT07465718 · 38 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 2028
Drug: TETA 4HCl formulation; D-Penicillamine · For: Wilson's Disease
Sites: Denver, Colorado; New Haven, Connecticut; Ann Arbor, Michigan · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dose omission19
- therapy interrupted17
- product storage error13
- drug ineffective11
- insurance issue11
- treatment noncompliance11
- condition aggravated10
- nausea10
- enteritis9
- hepato-lenticular degeneration9
- no adverse event9
- death8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 6 |
| 2007 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 14 |
| 2017 | 41 |
| 2018 | 20 |
| 2019 | 12 |
| 2020 | 17 |
| 2021 | 20 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 9 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Syprine (Trientine HCl)
2024 spending
$1.4M
Beneficiaries
n/a
61 claims
Per beneficiary
n/a
$198.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,666,049 |
| 2021 | $766,879 |
| 2022 | $617,408 |
| 2023 | $702,348 |
| 2024 | $1,437,525 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML, Czlonkowska A, Zuin M, et al. · Lancet Gastroenterol Hepatol 2022 · Clinical Trial, Phase III, Equivalence Trial
- The steady state pharmacokinetics of trientine in Wilson disease patients.
Pfeiffenberger J, Kruse C, Mutch P, et al. · Eur J Clin Pharmacol 2018 · Clinical Trial, Phase I
- Early neurological deterioration in Wilson's disease: a systematic literature review and meta-analysis.
Antos A, Czonkowska A, Smolinski L, et al. · Neurol Sci 2023 · Systematic Review, Meta-Analysis
- Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects.
Weiss KH, Thompson C, Dogterom P, et al. · Eur J Drug Metab Pharmacokinet 2021 · Clinical Trial, Phase I, Comparative Study
- Treatment of Wilson's disease with zinc: XV long-term follow-up studies.
Brewer GJ, Dick RD, Johnson VD, et al. · J Lab Clin Med 1998 · Clinical Trial
- Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C, Mathes T, Heeres MLS, et al. · Liver Int 2019 · Comparative Study, Meta-Analysis
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.